Nu-Med Plus, Inc. Annual Report: A Simple Guide

I’ve put together this guide to help you understand Nu-Med Plus, Inc.’s latest annual report. Think of this as a "cheat sheet" to help you decide if this company fits your portfolio.

1. What does this company do?

Nu-Med Plus develops systems to deliver nitric oxide, a gas used to treat lung conditions. Currently, hospitals use heavy, expensive gas tanks. Nu-Med’s technology aims to create this gas on-demand from a liquid source, removing the need for bulky tanks. They hold several patents for this technology and hope to license or sell it for use in hospitals and ambulances.

2. The Current Reality: "Paused"

Here is the most important point: All product development is currently suspended.

The company has promising prototypes but has hit a major roadblock: they have run out of money. They owe more than they own. They cannot afford the clinical testing or the expensive FDA approval process without a major cash injection. With only two employees—the CEO and the CFO—they rely on deferred pay and the personal efforts of consultants to keep the company running and compliant with SEC rules.

3. The "High-Stakes" Business Model

To sell devices for human use, they must gain FDA approval, which can cost up to $30 million.

• The Strategy: They hope to sell "research units" to labs. These units don't require the same strict FDA testing as medical devices, potentially providing early cash.
• The Reality Check: Management admits these sales would not generate enough profit to fund the massive costs of bringing a medical device to market.
• The Competition: They face industry giants like Linde and Mallinckrodt. These competitors have billions in value, dedicated regulatory teams, and established hospital networks.

4. Financial Health

As of mid-2025, the company is worth about $3.2 million. This is a "micro-cap" stock—it is tiny and very difficult to trade. The company has generated $0 in revenue for years. They spend very little only because operations have stopped, but they still pay for legal and accounting fees to stay listed on the stock exchange. They treat research costs as expenses immediately, reflecting the lack of a ready-to-sell product.

5. Key Risks

The company is clear about these significant risks:

• The Funding Gap: If they cannot raise money, they will shut down. Any future fundraising will likely involve issuing more shares, which reduces your ownership percentage.
• The "Big Fish" Problem: They compete against giants that can out-spend them on research and lobbying.
• Regulatory Hurdles: The FDA process is long and difficult. Even with funding, there is no guarantee their devices will pass safety standards.
• Management Experience: The team admits they lack the specific experience in clinical trials and large-scale manufacturing needed to bring a product to market.
• Liability: They carry no insurance for toxic leaks. Since nitric oxide is a reactive chemical, any accident could lead to lawsuits that exceed the company’s total assets, likely causing bankruptcy.

Bottom Line: Is this for you?

The company describes itself as "highly speculative." Because they are currently paused, have no revenue, and face significant regulatory and financial hurdles, they are years away from potential success. They explicitly warn that there is a high chance you could lose your entire investment. If you are looking for a stable, income-generating stock, this is likely not the right fit for your portfolio.